Compare EQ & JAGU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQ | JAGU |
|---|---|---|
| Founded | 2017 | 2022 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 63.2M |
| IPO Year | N/A | N/A |
| Metric | EQ | JAGU |
|---|---|---|
| Price | $1.71 | $2.95 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | 497.7K | ★ 798.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $2.63 |
| 52 Week High | $2.35 | $5.50 |
| Indicator | EQ | JAGU |
|---|---|---|
| Relative Strength Index (RSI) | 69.85 | N/A |
| Support Level | $1.53 | N/A |
| Resistance Level | $1.69 | N/A |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 98.78 | 0.00 |
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.